A novel strategy using healthy plasma infusions led to promising results in patients with mild to moderate Alzheimer’s disease, Alkahest recently announced. Stanford Medicine presented clinical data of its PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (NCT02256306) Nov. 4 at the 10th Clinical Trials on Alzheimer’s Disease conference in…
Aducanamab helps reduce amyloid plaques in Alzheimer’s patients who receive a gradually increasing dose of the therapy, its developer, Biogen, reports, citing results from the long-term extension of its ongoing Phase 1b study (NCT01677572). The potential treatment, also known as BIIB037, is a human monoclonal antibody derived from…
Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data presented during the recent 10th Clinical Trials on Alzheimer’s…
Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, which stems from additional analyses of data gathered in a Phase 2 trial of pimavanserin in Alzheimer’s patients, was…
Otsuka Pharmaceutical announced that it and Lundbeck will launch a third Phase 3 clinical trial of brexpiprazole to possibly treat agitation in patients with dementia linked to probable Alzheimer’s disease. Brexpiprazole, under the brand name Rexulti, was approved in the United States to treat people with schizophrenia and as an adjunct treatment…
Researchers have found that long-term use of opioids is not associated with an increased risk of Alzheimer’s disease (AD). The research was part of Finland’s nationwide MEDALZ study, and the findings were published in the journal Pain Medicine under the title “Is Alzheimer’s Disease Associated with Previous…
Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of success, according to a study published in the journal Cell Reports. A class of drugs, intended to block an enzyme…
A first-of-its-kind event, “A Women’s Health Summit: It Starts With the Brain,” set for today in New York, will focus on women’s brain health and Alzheimer’s disease. The summit is being co-organized by award-winning journalist Maria Shriver, founder of the Women’s Alzheimer’s Movement, and Nancy Dubuc, president and CEO…
Probiodrug‘s PQ912 decreased markers of inflammation and damage in the nerve cell connections of Alzheimer’s patients, according to a Phase 2a clinical trial. The company will present the results of the SAPHIR trial, which covered the therapy’s safety and effectiveness, at the 10th Clinical Trials on Alzheimer’s Disease Conference in…
AbbVie and Alector are partnering on developing and commercializing treatments for Alzheimer’s and other neurodegenerative diseases. Alector brings an immuno-neurology discovery platform to the partnership. AbbVie brings its expertise in research, development, and commercialization of therapies targeting Alzheimer’s. It has become increasingly clear that the immune system plays a key…
Get regular updates to your inbox.